

5th International Conference on Nutrition, Food Science and Health Management
7th World Summit on Virology, Microbiology & Infectious Disease

May 05, 2022 | Webinar



Alfredo Luis Fort

University of North Carolina, USA

Eat well, move well and feel well: The recipe for quality life and longevity

Although the track is “Nutrition and Obesity”, in reality this presentation covers the wider range of how proper nutrition, physical activity, and good feeling will not only prevent the new global “pandemic” of overweight and obesity, but will prevent and reduce the prevalence of cardiovascular disease (CVD), diabetes, cancer, addiction, suicide and other ailments increasingly affecting human beings in every corner of the world.

The presentation will first present data and statistics from demography, epidemiology and social psychology for the last 50 years, presenting important advances in living standards around the world contributing to increased life expectancy and longevity (despite existing inequalities). However, at the same time, we are witnessing the appearance of conditions such as stress and conflict, addiction and suicide, sedentarism and sleeplessness, compulsive eating of excessive rations of sugary and highly processed drinks and foods that are counteracting and tugging negatively over such advances.

Once these conditions and their devastating consequences

are presented, the presenter will highlight how each of the three corners of the triangle: food, activity and feeling, properly and adequately addressed and managed, will impact positively in our life. He will present a new paradigm: FIRM and WELL, made by Feeling Well, Ingesting Well, Resting Well and Moving Well, all of which will produce well – being and Long Life!

Speaker Biography

Alfredo Luis Fort is a Global Health physician, researcher and evaluator, specialized in, reproductive, maternal, neonatal, child and adolescent health, demography, population and gender equality, applied nutrition and early childhood development. He has conducted population and facility-based surveys and questionnaire design, project and program monitoring, evaluation and learning (MEL), and evidence generation for policy decision-making in many low- and middle-income countries. He holds a medical degree, an MSc and a PhD, and has worked in WHO Geneva, UNFPA New York and is professor of the University of North Carolina at Chapel Hill, USA, lecturer at international universities, an adviser to WHO and peer reviewer of international journals where he has also published.

alfredoluisfort@gmail.com

Received date: March 14, 2022; Accepted date: March 18, 2022; Publish date: May 10, 2022

5th International Conference on Nutrition, Food Science and Health Management
7th World Summit on Virology, Microbiology & Infectious Disease

May 05, 2022 | Webinar



George Huang* , Andrew Lam, Christine Tan, Liying Xie and Xiaodong Yang

Apexigen Inc., USA

A tetravalent antibody designed to prevent and treat all SARS-CoV-2 variants

Vaccines and antibodies are important therapeutics for preventing and treating covid-19. However, the continuous emergence of SARS-CoV-2 variants of concern poses a threat to the efficacy of existing vaccines and neutralizing antibodies. Indeed, the majority of the therapeutic antibodies that potently neutralized earlier, less-mutated SARS-CoV-2 variants such as Alpha, Gamma, and Delta do not neutralize the heavily mutated Omicron BA.1 and BA.2 variants. Using Apexigen's APXiMAB platform, we designed and developed a tetravalent antibody, APX901, that binds to the RBD of SARS-CoV-2 with high affinity ($K_d = 5.1 \times 10^{-10} M$) at four epitopes that are located at the top face and the inner face of the RBD. The tetravalency and multiple epitopes enable APX901 to achieve broader and more potent blocking and neutralization of not only Alpha, Gamma, Delta, but also and more importantly Omicron BA.1 and BA.2 variants. In addition to broad and potent blocking and neutralization activities to all SARS-CoV-2 variants tested, APX901 was

engineered to have an extended half-life and a desirable developability profile. The unique design and characteristics of the tetravalent antibody APX901 allow it to broadly block and neutralize known and emerging SARS-CoV-2 variants and to offer an innovative solution for the prevention and treatment of covid-19 infections.

Speaker Biography

George Huang is the Head of Antibody Discovery, Principal Scientist at Apexigen, where he leads the APXiMAB antibody discovery and engineering platform to discover and develop differentiated best-in-class therapeutic antibodies for Apexigen's pipeline projects. Previously, he was a Senior Scientist at AbbVie leading protein engineering projects in the areas of antibody humanization, engineering of novel antibody formats, and antibody developability characterizations. George received his PhD in Biochemistry and Cell Biology from Rice University and conducted post-doctoral research at the University of Texas Health Science Center at Houston, in the area of Cell Biology and Antibody Engineering.

ghuang@apexigen.com

Received date: March 14, 2022; **Accepted date:** March 18, 2022; **Publish date:** May 10, 2022